Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Biocon chairman Kiran Mazumdar-Shaw: 'This is indeed a significant inflection point in our globalization path.' Pfizer's David Simmons: 'We are excited to join…
GEN reported the partnership end, noting all rights to Univia and Glarvia reverted to Biocon and that Pfizer would continue biosimilars work internally — with…
GaBI reported Pfizer and Biocon ended the biosimilar insulin deal in March 2012 citing 'differing priorities,' with Biocon retaining the $100M upfront and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer/Biocon global commercialization agreement: $200M upfront + up to $150M development/regulatory milestones + sales-linked payments. Pfizer to commercialize Biocon's biosimilar insulins worldwide.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Biocon Limited (biosimilar insulin license) (this deal) | 2010 | $350M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2010 deals · Pfizer Inc. deals · Metabolic deals